M40403

M40403

A small superoxide dismutase mimetic that removes superoxides, converting toxic free radicals into O2 and H2O2, which are decomposed by catalase. It is being developed as a co-therapy with IL-2 for managing skin and kidney cancers, and has favourable therapeutic effects in animal models of acute myocardial infarction, stroke, inflammatory bowel disease, rheumatoid arthritis, diabetic microangiopathies and septic shock.
 
Pros
Lower molecular weight than SOD; penetrates cells and membranes easily; more stable; longer half-life; does not trigger an immune response.
References in periodicals archive ?
sup][18] The application of oxidative stress blockers including the mitochondrial protector, L-carnitine [sup][19] and melatonin [sup][20] in vivo , and specific antioxidants in vitro , including the SOD mimetic, M40403, and the nitric oxide synthase inhibitor, 7-nitroindazole, fully, or partially reversed the anesthetic-induced neurotoxicity.
The manganese superoxide dismutase mimetic, M40403, protects adult mice from lethal total body irradiation.
Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic, M40403.
Adding M40403 to IL-2 treatment kept blood pressure normal, which enabled researchers to double the dose of IL-2 in animal tests.
Besides reducing IL-2's side effects, M40403 exhibited anticancer activity, reports Wolfram E.
The lead candidates from this family, M40403 and M40419, are being tested in clinical trials for acute pain and refractory hypotension.
Salvemini D, Mazzon E, Dugo I, Riley DP, Serriano L, Caputi AP, Cuzzocrea S (2001) Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic, M40403.
M40403 is one of a proprietary family of small-molecule SOD mimetics developed by MetaPhore that are designed to selectively remove superoxide, a free radical that, in excess, has been shown to contribute to inflammatory pathways and to regulate cytokine release.
M40403 is one of a proprietary family of small-molecule SOD mimetics developed by MetaPhore that are designed to replicate the action of natural SOD enzymes, and selectively remove excess superoxide.
M40403 is one of a proprietary family of small-molecule SOD mimetics developed by MetaPhore that are designed to replicate the action of natural SOD enzymes, one of the body's primary defenses against free-radical damage to cells and tissues.
MetaPhore recently announced the successful completion of its first Phase I clinical trial with the SOD mimetic, M40403 (injectable), in normal healthy subjects.
The Phase I, double-blind, placebo-controlled clinical trial involved single, escalating doses of the enzyme mimetic drug M40403 administered intravenously in a total of 36 normal, healthy human subjects.